Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:age_group |
12 to 15 months
|
| gptkbp:availability |
widely available
|
| gptkbp:average_temperature |
2 to 8 degrees Celsius
|
| gptkbp:clinical_trial |
Phase IV
|
| gptkbp:community_health |
reduces incidence of diseases
|
| gptkbp:contraindication |
pregnancy
immunocompromised individuals |
| gptkbp:dosage_form |
4 to 6 years
|
| gptkbp:effective_date |
FDA approved
|
| gptkbp:first_introduced |
gptkb:1988
|
| gptkbp:formulation |
gptkb:liquid
|
| https://www.w3.org/2000/01/rdf-schema#label |
MMR II
|
| gptkbp:is_vulnerable_to |
generally positive
healthcare providers public awareness campaigns varies by location ongoing studies two doses safety concerns live attenuated government and private funding high effectiveness ongoing safety monitoring two doses recommended concerns about autism CDC guidelines available in clinics 78% for mumps 93% for measles 97% for rubella considered safe for most individuals monitoring for adverse events part of childhood immunization schedule significantly reduced disease outbreaks |
| gptkbp:manufacturer |
gptkb:Merck_&_Co.
|
| gptkbp:route_of_administration |
subcutaneous
|
| gptkbp:safety_measures |
VAERS
|
| gptkbp:side_effect |
fever
rash joint pain |
| gptkbp:targets |
gptkb:rubella
gptkb:measles mumps |
| gptkbp:vaccine_administration_guidelines |
follow CDC recommendations
|
| gptkbp:vaccine_category |
combination vaccine
|
| gptkbp:vaccine_impact_on_public_health |
reduces morbidity and mortality
|
| gptkbp:vaccine_legislation |
mandatory in many states
|
| gptkbp:vaccine_storage_requirements |
requires refrigeration
|
| gptkbp:website |
upper arm
|
| gptkbp:bfsParent |
gptkb:Merck_Vaccines
|
| gptkbp:bfsLayer |
6
|